Core One Labs Acquires Akome Biotech

Core One Labs Acquires Awakened Biosciences

February 11, 2022

Biotechnology

Core One Labs Inc. (CSE: COOL) has completed the acquisition of all outstanding share capital of Awakened Biosciences Inc., adding Awakened's provisional patents and novel synthetic psilocybin production technologies to Core One's portfolio. The deal expands Core One's R&D and manufacturing capabilities in psychedelic therapeutics and secures IP that could enable lower-cost, scalable production and potential near-term revenue from non-controlled psilocybin-based compounds.

Core One Labs Acquires New Path Laboratories

December 23, 2021

Food & Beverage

Core One Labs Inc. has completed the acquisition of all outstanding share capital of New Path Laboratories Inc., a British Columbia-based developer and manufacturer of natural health products and functional mushroom dietary supplements. The deal was paid in common shares of Core One and is intended to expand Core One's presence in the functional mushrooms market and add retail distribution channels to generate sales revenue.

Quanterix Corporation Acquires Akoya Biosciences

July 8, 2025

Medical Devices

Quanterix Corporation has completed its acquisition of Akoya Biosciences, combining Quanterix's ultra‑sensitive blood biomarker detection platform with Akoya's spatial biology imaging and reagents. Under the amended merger agreement, Quanterix issued approximately 7.8 million shares and paid about $20 million in cash to Akoya equity holders; the combined business is expected to expand the company's served addressable market and accelerate the path to profitability.

Ginkgo Bioworks Acquires Assets from Bitome

June 6, 2022

Biotechnology

Ginkgo Bioworks acquired certain assets from Bitome, a Boston-based developer of real-time metabolite monitoring technology, to integrate continuous metabolite monitoring into its cell engineering platform. The acquisition is intended to accelerate design-build-test-learn cycles and bioprocess optimization across Ginkgo’s portfolio of cell programs by providing real-time metabolic data and ML-driven insights.

Arcline Investment Management Acquires Majority Interest in Akron Biotechnology

September 11, 2019

Biotechnology

Arcline Investment Management has acquired a majority interest in Akron Biotechnology LLC, a supplier of cGMP-compliant materials and services for cell and gene therapy manufacturers. Akron will remain led by founder and CEO Dr. Claudia Zylberberg, and Arcline plans to expand Akron's manufacturing capacity and pursue complementary acquisitions to build a platform in regenerative medicine.

Exos Acquires Infinite Athlete and Biocore

October 30, 2025

Healthcare Services

Exos has acquired sports technology company Infinite Athlete and its subsidiary Biocore, bringing the businesses under the Exos brand to expand the company's tech-enabled human performance capabilities. The deal is backed by private equity investors BDT & MSD Partners and Madrone Capital Partners and combines Exos' coaching and workplace performance platform with Infinite Athlete's AI-driven data science and Biocore's biomechanical engineering and testing.